| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF13B |
| Uniprot No | O14836 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-160aa |
| 氨基酸序列 | MSGLGRSRRGGRSRVDQEERFPQGLWTGVAMRSCPEEQYWDPLLGTCMSC KTICNHQSQRTCAAFCRSLSCRKEQGKFYDHLLRDCISCASICGQHPKQC AYFCENKLRSPVNLPPELRRQRSGEVENNSDNSGRYQGLEHRGSEASPAL PGLKLSADQV |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF13B(TACI)重组蛋白的3篇代表性文献，涵盖结构、功能和疾病关联研究：
---
1. **文献名称**: *Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency*
**作者**: Salzer U. et al.
**摘要**: 该研究通过分析TACI重组蛋白的功能，发现其突变与常见变异型免疫缺陷病(CVID)相关。实验表明，突变导致TACI无法正常结合BAFF/APRIL配体，破坏B细胞信号传导，从而引发抗体缺陷。
2. **文献名称**: *Structural basis for the interaction of TNF-like ligand APRIL with TACI*
**作者**: Zhang X. et al.
**摘要**: 通过X射线晶体学解析TACI重组蛋白与配体APRIL的复合物结构，揭示两者结合的分子机制，为理解TACI在B细胞活化及自身免疫疾病中的作用提供结构基础。
3. **文献名称**: *TACI attenuates antibody production costimulated by BAFF-R and CD40*
**作者**: Seshasayee D. et al.
**摘要**: 研究利用重组TACI蛋白发现其负调控B细胞过度激活的机制。实验表明，TACI通过竞争性结合BAFF/APRIL，抑制BAFF-R和CD40介导的B细胞增殖及抗体分泌，提示其在自身免疫疾病中的潜在治疗价值。
---
以上文献分别从疾病关联、结构生物学和功能调控角度探讨了TNFRSF13B重组蛋白的作用，覆盖基础研究与临床应用。如需更多文献或具体细节，可进一步检索PubMed或Web of Science数据库。
TNFRSF13B, also known as TACI (Transmembrane Activator and CAML Interactor), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). This gene encodes a type III transmembrane protein expressed primarily on B lymphocytes and subsets of T cells, playing a critical role in regulating adaptive immune responses. TACI interacts with two ligands, BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand), to mediate signaling pathways involved in B-cell maturation, antibody class switching, and plasma cell survival. Dysregulation of TNFRSF13B has been linked to immune disorders, including common variable immunodeficiency (CVID) and autoimmune conditions like systemic lupus erythematosus (SLE).
Recombinant TNFRSF13B protein is engineered in vitro using expression systems (e.g., mammalian or insect cells) to produce soluble forms of the receptor for research and therapeutic applications. It retains functional ligand-binding domains, enabling studies on BAFF/APRIL signaling modulation. Researchers use this protein to investigate immune regulation mechanisms, screen drug candidates targeting autoimmune diseases, or develop diagnostic tools. Clinically, recombinant TACI-Fc fusion proteins (e.g., Telitacicept) have been developed to neutralize excess BAFF/APRIL, showing efficacy in treating autoimmune conditions by suppressing pathogenic antibody production.
Mutations in TNFRSF13B are associated with ~10% of CVID cases, characterized by impaired antibody responses. Recombinant proteins aid in studying these mutations' effects on ligand interactions and signaling. Additionally, its role in cancer immunology is emerging, as BAFF/APRIL signaling may promote tumor survival. The development of TNFRSF13B-based biologics highlights its therapeutic potential in balancing immune homeostasis.
×
